Allogeneic Human Neural Stem Cells for Improved Therapeutic Delivery to Peritoneal Ovarian Cancer

Jennifer Batalla-Covello  
City of Hope National Medical Center

Wafa Abidi  
City of Hope National Medical Center

Hoi Wa Ngai  
City of Hope National Medical Center

Caitlyn Hyde  
City of Hope National Medical Center

Diana Machado  
City of Hope National Medical Center

Asma Abdul Majid  
City of Hope National Medical Center

Yanan Kang  
City of Hope Comprehensive Cancer Center Duarte

Mohamed Hammad  
City of Hope

Linda Flores  
City of Hope National Medical Center

Gregory Copeland  
City of Hope National Medical Center

Thanh Dellinger  
City of Hope National Medical Center

Ernest Han  
City of Hope National Medical Center

Jacob Berlin  
City of Hope

Karen Aboody  
City of Hope National Medical Center

Rachael Mooney (mooney@coh.org)  
City of Hope  https://orcid.org/0000-0002-9069-0206

Research
Abstract

Background: Immortalized, clonal HB1.F3.CD21 human neural stem/progenitor cells (NSCs), loaded with therapeutic cargo prior to intraperitoneal (IP) injection, have been shown to improve the delivery and efficacy of therapeutic agents in pre-clinical models of stage III ovarian cancer. In previous studies, the distribution and efficacy of the NSC-delivered cargo has been examined; however, the fate of the NSCs has not yet been explored. Methods: To monitor NSC tropism, we used an unconventional method of quantifying endocytosed gold nanorods to overcome the weaknesses of existing cell-tracking technologies. Results: Here, we report efficient tumor tropism of HB1.F3.CD21 NSCs, showing that they primarily distribute to the tumor stroma surrounding individual tumor foci within 3 hours after injection, reaching up to 95% of IP metastases without localizing to healthy tissue. Furthermore, we demonstrate that these NSCs are non-tumorigenic and non-immunogenic within the peritoneal setting. Conclusions: Their efficient tropism, combined with their promising clinical safety features and potential for cost-effective scale-up, positions this NSC line as a practical, off-the-shelf platform to improve the delivery of a myriad of peritoneal cancer therapeutics.

Background

Ovarian cancer is a deadly disease that affects approximately 22,000 women in the United States per year (1). For patients with stage III ovarian cancer, in which tumors have metastasized to the abdominal cavity, the five-year survival rate is only 34% (1). Intraperitoneal (IP) chemotherapy confers a significant survival advantage in these patients, but its widespread use has been limited by its toxic side effects, which often prevent treatment completion. A targeted delivery system to concentrate therapeutics specifically at ovarian tumor sites could substantially enhance treatment efficacy and reduce undesirable side effects, improving quality of life (2). Furthermore, standard of care includes invasive surgical debulking. This process only removes macroscopic tumors, leaving behind microscopic tumors. A targeted therapeutic delivery system with better distribution would help target those micro-metastases post-surgery.

Tumor-tropic cell carriers, which have a propensity to migrate to tumor sites, have shown promise as a tumor-targeted delivery system. For example, we and others have demonstrated that cell carriers afford advantages over free nanoparticle (NP) delivery in the IP cavity. Specifically, mesenchymal stem cells (MSCs), neural stem/progenitor cells (NSCs), T-cells, and macrophages can dramatically increase the efficiency and number of therapeutic NPs that localize to tumors in vitro and in vivo (3–7). Cell-mediated tumor tropism is not passive, but rather an active, discriminating process mediated by a myriad of tumor-localized signals (8). Because cell carriers are approximately 10 μm in diameter, they mainly deposit on the peritoneal surface rather than pass through it (9,10). Furthermore, cell carriers injected into the IP cavity can increase the retention of small (~100-nm) NPs from mere hours to several days (11).

Autologous MSCs, which have been the predominant cell type investigated for peritoneal therapeutic delivery (12,13), can be isolated from a patient's bone marrow or adipose tissues, expanded and modified ex vivo, and re-administered. However, there are major drawbacks to the use of MSCs, including that they...
are composed of heterogeneous cell populations, have poorly reproducible ex vivo loading capacities, and lose their tumor-homing properties after 5–6 passages (13). Moreover, the amount and quality of MSCs that can be isolated depend critically on patient age and health status, and it can take two weeks after isolation to generate a sufficient number of cells for treatment (13). In addition, it was recently reported that 20% of expanded MSCs had abnormal karyotypes (13), which is of deep concern as the confirmed non-tumorigenicity of any clinical stem cell therapy is of paramount importance. Consequently, although autologous MSCs may be feasible therapeutic delivery vehicles for smaller phase I trials, they represent an inefficient and poorly reproducible approach that will be difficult to pass through regulatory hurdles and meet the scale-up requirements necessary for phase II and III trials (13). Therefore, developing a more clinically viable strategy to deliver therapeutic cargo selectively to tumor sites is critical.

In our previous work (14,15), we investigated the use of an established tumor-tropic human clonal NSC line, HB1.F3.CD21, for targeted IP therapy in orthotopic mouse models of high-grade serous ovarian cancer, the most common histotype of stage III peritoneal disease. These NSCs are chromosomally and functionally stable over time and passage, HLA class II-negative, and their clinical safety, tumor tropism, and tumor-localized chemotherapy production in recurrent glioma patients has been demonstrated (16). Importantly, this NSC line has established standard operating procedures for scaled-up production that are more efficient, reproducible, and economical than those used for autologous cells. Thus, the line can be expanded, modified, and banked as an “off-the-shelf” product, readily available for trials at multiple sites (17). Although we previously demonstrated that the IP administration of these NSCs improves the delivery and therapeutic efficacy of drug-loaded NPs (14,15) and oncolytic viruses (18) in ovarian metastases, additional studies are required to determine the efficiency of each administration, degree of tumor coverage, penetration of the tumor stroma, and potential unintended tumorigenic/immunogenic effects of these NSCs.

In the present study, we conduct comprehensive pharmacokinetic and biodistribution assessments to probe the efficiency, peritoneal distribution, tumorigenicity, and immunogenicity of this NSC-based therapeutic delivery platform. We investigate NSC tumor tropism in both immunodeficient and immunocompetent orthotopic mouse models of IP ovarian metastases. Using these models, we confirm our previous observation that NSCs localize only to tumor nodules and not to normal tissues (14,18). We also demonstrate that HB1.F3.CD21 NSCs target ovarian metastases with remarkable efficiency and selectivity, positioning this cell line as an excellent delivery platform to improve the therapeutic index of IP anticancer treatments.

Methods

**Cell Culture:** The v-myc immortalized, clonal human HB1.F3.CD21 NSC line (approved by the Food and Drug Administration for human glioma clinical trials via local injection, Identifier: NCT01172964), was obtained from Dr. Seung Kim (University of British Columbia, Canada). The NSCs were further modified to produce NSC.eGFP.fluc cells expressing green fluorescent protein (eGFP) and firefly luciferase (fluc), as
previously described (19). The ID8 murine ovarian cancer line was obtained from Dr. Katherine Roby (University of Kansas). These cells were further modified using a PJ01668-eGFP-fluc-epHIV7 lentiviral vector (159e6 TU/ML; VF0716) generously provided by Dr. Christine Brown (City of Hope) to produce ID8.eGFP:fluc cells. Reporter gene expression and tumorigenicity were confirmed for the ID8.eGFP:fluc line prior to study initiation (Supplementary Fig.1). eGFP and fluc-expressing OVCAR8 human ovarian cancer cells (OVCAR8.eGFP:fluc) were generously provided by Dr. Carlotta Glackin (City of Hope). The NSC and ID8 cell lines were cultured in DMEM (Invitrogen) and the OVCAR8 cell line was cultured in RPMI basal media; all media was supplemented with 10% fetal bovine serum (Gemini Bio), 1% L-glutamine (Invitrogen), and 1% penicillin-streptomycin (Invitrogen). All cells were maintained at 37°C in a humidified incubator (Thermo Electron Corporation) containing 6% CO₂ and passaged using a 0.25% trypsin and EDTA solution (Invitrogen) when they reached 80% confluence, and media was changed every 2–3 days.

**In Vivo NSC Administration and Tracking in Ovarian Cancer Models:** Mice were maintained under specific pathogen-free conditions in the City of Hope Animal Resource Center, an AAALAC-accredited facility. All procedures were reviewed and approved by the City of Hope Animal Care Committee. For our immunodeficient model, 6–8-week-old female nude mice (The Jackson Laboratory) were inoculated with 2 × 10⁶ OVCAR8.eGFP:fluc cells via IP injection. For our immunocompetent model, 7–8 week old female C57Bl/6 mice (B6, National Cancer Institute [NCI]) were inoculated with 5 × 10⁶ ID8.eGFP:fluc cells via IP injection. After tumor development (3 weeks for OVCAR8, and 6 weeks for ID8), mice received NSCs (10,000–1 × 10⁷ total) labeled with lipophilic tracers (DiR; Thermo Fisher Scientific), 811-nm MUTAB-conjugated gold nanorods (AuNRs; Nanopartz) (14)). At select time points after administration of NSCs, mice underwent live-animal imaging (described below), then peritoneal lavage fluid was collected, as previously described (20), and tumors were harvested from major organs (liver, kidney, stomach, intestines, and mesentery) and processed for inductively coupled plasma mass spectrometry (ICP-MS) quantification or fluorescence imaging, as described below.

**Live-Animal Imaging:** Tumor burden and NSC localization were evaluated via bioluminescence imaging. To determine if AuNRs affect NSC viability or tropism in vivo, OVCAR8.eGFP:fluc tumor cells were used to inoculate nude mice and DiR-labeled NSCs with or without AuNRs were injected IP. To track NSC clearance in another experimental subset of mice, unlabeled tumor cells were used to inoculate nude mice, and DiR-labeled NSC.eGFP:fluc cells were inject IP. Prior to imaging, mice were anesthetized by isoflurane (1.5 L/oxygen, 4% isoflurane) in an induction chamber and injected IP with D-luciferin substrate suspended in PBS at 4.29 mg/mouse. Mice were maintained under anesthesia in chamber, and NSCs were imaged 7 min after luciferin injection using a SPECTRAL Ami X charge-coupled device camera coupled to Ami X image acquisition and analysis software. Light emission was measured over an integration time of 30 s.

**ICP-MS Quantification of AuNRs:** Concentrations of gold (AuNRs) in tumors and peritoneal lavage fluid were determined using an Agilent 8800 inductively coupled plasma triple quadrupole mass spectrometer. Briefly, each sample was digested with 70% HNO₃ at 80°C for 16 h. Samples were diluted with 2% HNO₃
prior to injection into the mass spectrometer, and the detected signals were determined based on standard curves made using serial dilutions of gold (100 ppm) standard solutions (Spex Certiprep) in 1% HCl and 2% HNO₃. To determine the percentage of AuNRs that localized to tumors vs. the lavage fluid, their concentrations were normalized to the concentrations detected in the original cell suspension that was injected into each mouse.

**Fluorescence Imaging:** Tumors were frozen in Tissue Tek OCT (Sakura Finetek USA) and sectioned on a Leica CM1510 S cryostat (Leica Biosystems). Sections (10 μm) were collected on positively charged slides (Thermo Fisher Scientific), immunostained for active caspase-3/7 (AB3626; Chemicon), counterstained with DAPI (1 μg/mL; Sigma), and imaged using a Zeiss Axio Observer Z1 fluorescence microscope (Zeiss Microscopy). For 3D histological reconstruction to visualize NSC penetration, a subset of tumors was sectioned into 10μm thick slices, imaged in their entirety at 200 μm intervals, and virtually reconstructed using Reconstruct software (21).

**Mixed Lymphocyte Reaction:** To assess the immunogenicity of the NSCs in vitro, peripheral blood mononuclear cells (PBMCs) were incubated with NSCs and their degranulation measured, as previously described (22). Briefly, PBMCs were isolated from seven healthy volunteers, using standard Ficoll density gradient centrifugation, and cryopreserved. Thawed aliquots of PBMCs were co-cultured with NSCs (1:1 final ratio), and FITC-conjugated antibodies against CD107a and CD107b (BD Pharmingen) were added to the cultures, followed by a monensin-containing protein transport inhibitor (GolgiStop; BD Biosciences). Cells were then stained with antibodies against CD3, CD4, CD56, CD16, CD14, and CD19 (BD Pharmingen) and analyzed using a Gallios flow cytometer (Beckman Coulter). Monocytes and B cells that expressed CD14 and CD19 were excluded. PBMCs stimulated with phorbol myristate acetate (PMA; 50 ng/ml) and phytohemagglutinin (PHA; 1 μg/ml) served as positive controls.

**Flow Cytometric Analysis of PD-L1 and CD47 Expression:** Trypsinized NSCs were stained with PE/Dazzle594-conjugated antibodies against human PD-L1 (clone 29E2A3) and CD47 (clone CC2C6) and their respective isotype controls (BioLegend). All flow samples were acquired using a Guava EasyCyte flow cytometer (Millipore). Histograms were generated using FlowJo (Tree Star).

**Tumorigenicity:** To determine if IP injections of NSCs altered tumor progression in vivo, nude mice were inoculated IP with OVCAR8.eGFP.ﬂuc cells. After allowing tumors to progress unaltered for one or three weeks (early and late tumor stages, respectively), mice received IP injections of 2 × 10⁷ NSCs twice a week for three weeks. After the last week of treatment, mice were euthanized and tumors harvested, pooled, and weighed in pre-tared tubes.

**Statistical Analysis:** Data are presented as mean ± SEM, and statistical significance ($p < 0.05$) was determined using two-tailed Student’s t-tests.

**Results**
**AuNR-based Tracking of NSC Tumor Tropism Within the Peritoneal Cavity:** In mouse models, tumor cells inoculated into the peritoneal cavity are carried by the physiological movement of the peritoneal fluid to seed the greater omentum, followed by the serosal surfaces of the liver, kidney, intestines, diaphragm, and peritoneum. The tumors that are formed consist of small (0.5–5-mm) nodules scattered over the peritoneal surface. Thus, it was necessary to identify a tracking method that is sensitive enough to quantify the presence of NSCs at individual nodules. In preliminary studies, we found that the signal afforded by membrane dyes and fluorescent gene markers was suboptimal for the sensitive quantification of NSCs localized to IP tumors (Supplemental Fig. 3). Instead, we labeled NSCs with internalized AuNRs (Fig. 1A), which provide an NSC-specific signal that can be assessed quantitatively with high sensitivity using ICP-MS.

We previously showed that AuNRs do not impair NSC viability or tropism in vitro (23,24). Here, we utilized live-animal imaging to demonstrate that DiR-stained NSCs labeled with AuNRs are able to migrate towards tumors within the peritoneal setting in vivo (Fig. 1B). We then validated the detection method by injecting different doses of AuNR loaded NSC varied from $1 \times 10^4$ to $1 \times 10^7$. The minimum number of NSC.AuNRs required to produce measurable AuNR levels in harvested tumors (pooled) was about 100,000 (Fig. 1C), and detection was dose-responsive up to an injected dose of $1 \times 10^7$ NSCs, which is the maximum practical dose based on scale-up considerations for human trials (Fig. 1C).

To determine the efficiency of NSC.AuNRs migration to IP tumors, we quantified the AuNR content within suspensions of $1 \times 10^7$ NSCs (total dose), which were then injected into the peritoneal cavities of nude mice bearing OVCAR8 tumors. Tumors were harvested at 1 and 24 h after NSC.AuNRs injection to assess their Au content. ICP-MS analysis revealed that 60% ± 20% of the injected dose was localized to the tumors by 24 h (Fig. 1D). To confirm that the tumor-localized AuNR signal could be attributed to NSCs, we also evaluated control mice injected with a matching dose of free AuNRs and observed a signal 52 ± 13% lower than that of the NSC.AuNRs at 24 h.

We next tested if NSC localization to tumor sites could be enhanced by splitting the dose of $1 \times 10^7$ NSC.AuNRs into two or three injections administered over a 24 h period (Fig. 1E). We found no significant differences in the quantity of NSC.AuNRs localized to the tumor when they were administered as a single bolus dose rather than in multiple injections.

**Kinetics of NSC Tropism and Cargo Delivery:** The migration of NSCs from the peritoneal cavity to the tumors could be observed macroscopically, because the AuNRs are visibly black. This resulted in localized NSCs altering the tumor appearance from white to grayish within 24 hours (Fig. 2A). Conversely, the pellet of cells harvested from the lavage fluid was black soon after IP administration of NSC.AuNRs but white within 24 hours (Fig. 2A). To further evaluate NSC tropism kinetics, we quantified Au levels within tumors and peritoneal lavage fluid collected at several time points after IP administration of NSC.AuNRs in OVCAR8 tumor-bearing nude mice. ICP-MS analysis demonstrated that 60 ± 20% of the NSC dose localized to tumors within 2–3 h after IP administration (Fig. 2B). At all tested time points (1–72 h), 70–80% of the injected NSCs were accounted for in either the lavage fluid or the tumors.
NSC Tumor Coverage and Biodistribution: To assess the extent of NSC tumor coverage, we isolated individual IP tumor nodules and used ICP-MS to determine the number of NSCs contained therein. After IP administration of $1 \times 10^7$ NSC.AuNRs to immunodeficient (nude) or immunocompetent (B6) mice bearing peritoneal ovarian metastases (OVCAR8 and ID8, respectively), more than 95% of tumor metastases were found to contain at least 10 NSCs, with each tumor containing a median of 425 NSCs (Fig. 3A). We also evaluated the distribution of NSC.AuNRs across tumors associated with specific organs. AuNR levels were particularly high in the omentum (Fig. 3B), the primary site of ovarian cancer metastases in patients (25), which accounted for approximately 40% of the collected tumor tissue by mass. To evaluate the distribution of NSCs within individual tumor nodules, we performed serial cryosectioning, fluorescence imaging, and 3D tumor reconstruction. The NSCs were generally distributed at the peritumoral stroma, with some penetration into the tumor parenchyma if there was also stromal infiltration (Fig. 3C–D). Consistent with our previous findings (14), no obvious off-target distribution was observed in any cryosectioned tissue samples (Supplementary Fig. 2). NSC.AuNR distribution to the tumor-associated stroma was observable macroscopically as a grayish colored tissue connecting individual tumor metastasis (Fig. 3E).

NSC Immunogenicity and Tumorigenicity: HB1.F3.CD21 NSCs are generally considered to have negligible immunogenicity. They inherently express low levels of MHC class I antigens and undetectable levels of MHC class II antigens. We observed negligible immunological recognition of parental NSCs by PBMCs in vitro (Fig. 4A). The NSCs also had low expression of PD-L1 and CD47 (Fig. 4B), presumably reducing their visibility to the innate and adaptive immune systems, respectively. In addition, we demonstrated that biweekly IP administrations of $2 \times 10^7$ NSCs (greater than the maximum clinical dose) did not promote ovarian tumor growth in immunodeficient (nude) mice bearing early- or late-stage OVCAR8 tumors (Fig. 4C).

Discussion

Collectively, our results demonstrate the remarkable extent to which HB1.F3.CD21 NSCs rapidly and selectively home to an overwhelming majority of peritoneal metastases. Here, we discuss our major findings in the context of current literature.

IP administered NSCs Localize Efficiently to Peritoneal Metastases: Although IP-administered NSCs have the potential to migrate anywhere on the vast peritoneal surface area ($1.7 \text{ m}^2$), our ICP-MS based quantification of NSC-associated AuNRs unexpectedly showed that an impressive 70–80% of NSCs localized to tumors, reaching up to 95% within 3 h after injection (Fig. 2B, 3A). One possible explanation for this tumor-specific localization is that the healthy mesothelium is protected by a layer of anti-adhesive proteoglycans, whereas tumor disruptions expose the underlying basement membrane, revealing extracellular matrix substrates (e.g., collagen I/IV, fibronectin, hyaluronan, and laminin) that can be bound by CD44 (26) and $\alpha_5\beta_1$ integrins (27) expressed by the HB1.F3.CD.21 NSCs. Because this study focused
only on intra-abdominal tumors and peritoneal lavage fluid, we were unable to account for the distribution of approximately 20% of injected NSCs. A minority of these NSCs may have been cleared from the abdomen through either the general circulation or lymphatic systems.

The behavior of NSCs, including their pharmacokinetic and biological properties, can be affected by the mode of administration (28–30). While intravenous administration offers several clinical advantages including ease of delivery and access to systemic metastasis, local IP administration is often pursued in the ovarian cancer setting to increasing the bioavailability of treatments at the target site. For example, a landmark clinical trial reported a significant survival benefit for ovarian cancer patients who had undergone a combination of intravenous (IV) and intraperitoneal (IP) cisplatin and paclitaxel as compared to IV paclitaxel and cisplatin alone(31). Local IP administration was chosen for the current study because most stem cell-based therapies that have progressed to late-stage clinical trials have used local administration (i.e., intracranial, intrathecal, intralesional, and endocardial)(31). Furthermore, we have previously demonstrated that that when NSCs are administered IV rather than IP, little to no NSCs are observed in tumors in the IP cavity (14). Systemic administration of stem cells still has key challenges including the instant blood-mediated inflammatory reaction (triggers coagulation), the pulmonary bypass barrier, and insufficient residence time at the target site(32).

We used the unconventional method of quantifying endocytosed AuNRs to monitor NSC tropism in order to overcome the weaknesses of existing cell-tracking technologies. Although the NSCs are engineered to express both eGFP and ffluc, given the resolution limits of live-animal imaging, these markers do not permit sensitive, quantitative NSC detection. Live animal imaging for ovarian tumor models can also be particularly troublesome as the depth and location of the tumors around the IP organs can limit the signal detection.. Furthermore, tumor and stromal DNA/cell counts overwhelm NSC-specific signals, so the number of NSCs present in tumor tissues is not reliably discernable using PCR or FACS. In addition, membrane dyes cannot be used without a complementary approach due to the possibility of **dye transfer from injected cells to host cells as well as the possibility of photo-bleaching and fluorophore instability after fixative methods** (33). In contrast, inorganic NP trackers provide a better balance of sensitivity, dynamic range, and stability for assessing the distribution of IP-administered NSCs as there is no background signal to hinder quantification. Importantly, this method also enables the macroscopic observation of NSC migration, as well as the ability to assess NSC cargo delivery (Fig. 1A,2A).

**NSCs Provide an Efficient Therapeutic Cargo Delivery System:** Our results demonstrate that the impressive tumor tropism of NSCs to IP metastases may significantly advance peritoneal chemotherapy by guiding the delivery of pre-loaded therapeutic cargo. We observed that, whereas the localization of NPs to tumors is low when they are delivered freely (perhaps because they are engulfed by peritoneal or tumor-associated macrophages), their tumor localization was significantly (more than 60%) greater when they were delivered within NSCs (Fig. 1D). We believe that this improvement can be generalized to other free vs. NSC-delivered therapeutic payloads. For example, we have previously reported improved NSC-mediated drug delivery of two standard-of-care chemotherapeutic drugs, cisplatin (14) and paclitaxel (PTX)(15) to peritoneal metastases; as well as two oncolytic viruses (34,35). This delivery system can not
only improve tumor localization, but also potentially reduce toxicity and prolong release of therapeutic reagent.

One critical insight yielded by the current study was that the NSCs localized primarily to the peritumoral stroma, with limited penetration into the tumor parenchyma (Fig. 3E). Thus, it is possible that improving the delivery of a drug to tumor nodules using NSCs may not be sufficient to improve its efficacy if other parameters dominate the response to treatment. For example, NSC-mediated drug delivery only improved the therapeutic efficacy of PTX (15) but not cisplatin (unpublished data). Other important parameters include: diffusion limits [cisplatin (200 cell layers) vs PTX (80 layers)(36)]; peritoneal-to-plasma area under the concentration-time curve ratio [cisplatin (7.8-21) (37,38) vs PTX (853) (39)]; treatment schedule [cisplatin (slow release, treated weekly) vs PTX (burst release, treated bi-weekly)]; impaired biological activity of cisplatin after release from NSCs, microenvironmental priming by PTX that improves drug penetration or immune stimulation upon repeated dose cycles (40–44). It will be important to consider and address these factors when selecting and developing therapeutic cargo for effective NSC delivery. Conversely, co-localization of NSCs to the tumor stroma provides an advantage in targeting the tumor stroma components that support tumor growth and metastasis (45). This can also be exploited to deliver immunotherapeutic reagents in a targeted setting, preventing systemic disadvantages of immunotherapy.

**NSC Safety Considerations:** Our result shows that HB1.F3.CD21 NSCs are non-tumorigenic in the peritoneal setting (Fig. 4C), consistent with our current clinical data in the glioma setting, as patients in phase I trials of allogeneic NSC-mediated enzyme/prodrug and CRAd-S-pk7 treatments have tolerated multiple intracranial administrations without adverse events or evidence of secondary tumorigenicity (16). In stark contrast, MSCs have been reported to functionally engraft into peritoneal organs (46,47), and can promote ovarian tumor growth by inducing the expression of IL-1, associating with macrophages, and transforming into carcinoma-associated MSCs (48). IP MSC administration has also been shown to increase pro-inflammatory cytokines in mice, triggering such dramatic omental immune cell influx that the organ doubled in weight (49). The results presented here show that NSCs induce negligible immunological recognition *in vitro* (Fig. 4A); however, further investigation of the potential immunomodulatory effects of NSCs within the IP cavity will be important within the context of future therapeutic efficacy studies, particularly for repeated NSC administrations.

Although autologous mesenchymal stem cells have also been used clinically to improve viral delivery to ovarian metastases (12), our allogeneic, off-the-shelf cell NSC line has essential practical advantages that enable cost-effective scale-up and greater reproducibility between patients. Following extensive characterization of the HB1.F3.CD NSC line, (50) we have already pioneered the clinical translation of genetically modified NSCs for four cancer (glioma and neuroblastoma) therapies (51). We have experience expanding, modifying, and banking these NSCs as “off-the-shelf” products, readily available for large trials at multiple sites. As NSC-based therapies progress into the clinic for targeted cancer treatment within the peritoneal setting, understanding the pharmacokinetics of the NSCs administered into this setting is important prior to performing IND-enabling studies involving NSCs modified with a therapeutic. Our plan is to streamline the translation of our existing therapeutic approaches to first-in-
human phase I trials for stage III ovarian cancer patients who fail surgical and chemotherapy standard of care, taking advantage of the Good Manufacturing Practices (GMP) standard operating procedures (SOPs) established for our ongoing clinical studies in other cancer settings.

**Conclusion**

This allogeneic, immortalized, GMP-grade NSC line has significant practical and economic advantages over autologous cell-carriers. It provides a non-tumorigenic, “off-the-shelf” platform that is readily available for modification, scale-up, and banking. Furthermore, it is amenable to the delivery of a broad array of therapeutic payloads within the peritoneal cavity. Our translational interest is in developing these cells for improved delivery of drug-loaded NPs, oncolytic viruses, and other promising therapeutic cargo, including bispecific T-cell engagers, small interfering RNA, and antibodies to patients with abdominal metastatic disease. Our long-term vision is to introduce cargo-loaded NSCs after surgical debulking. Surgical trauma creates disruptions to the patient’s mesothelial layer which serve as privileged sites for cancer cell attachment (52,53). However, we anticipate that NSCs will also be attracted to these regions and may be able to deliver a therapeutic dose strong enough to eliminate the attached tumor cells, thus preventing new tumor development.

**Declarations**

_Ethics approval and consent to participate: N/A_

_Consent for publication: N/A_

_Availability of data and materials: _All data generated or analyzed during this study are included in this published article [and its supplementary information files]._

_Competing Interests: _K.S.A., J.B., and R.M. disclose intellectual property with City of Hope and Harvard Patents. All other authors declare no competing interests._

_Funding: _This work was supported by the Rosalinde and Arthur Gilbert Foundation, City of Hope Women's Cancer Program, the California Institute of Regenerative Medicine Training Program (grant EDUC2-08383, TRAN1-11544), the Alvarez Family Foundation, the Anthony F. and Susan M. Markel Foundation, the Daphna and Richard Ziman Family Foundation, the National Cancer Institute (grant 1R01CA197359), the H.N. and Frances C. Berger Foundation, and the Norman and Melinda Payson Fellowship. Inductively coupled mass spectrometry and mixed lymphocyte reactions were performed by the City of Hope Analytical Pharmacology Core, which is supported by the National Cancer Institute of the National Institutes of Health under award number P30CA033572._

_Authors’ contributions: _Jennifer Batalla-Covello: Design, Collection of data, Manuscript writing; Wafa Abidi: Collection and analysis of data; Hoi Wa Ngai: Assembly of data; Yanan Kang: Assembly of data; Caitlyn Hyde: Collection of data; Diana Machado: Collection of data; Asma Abdul-Majid: Collection of
Acknowledgements: We thank scientific editor Kerin K. Higa, Ph.D.

Abbreviations

**AuNR**: gold nanorod; **NSC**: neural stem cell; **MSC**: mesenchymal stem cell; **RNA**: Ribonucleic acid; **DNA**: Deoxyribonucleic acid; **NP**: nanoparticle; **GMP**: good manufacturing practice; **IL-1**: Interleukin 1; **PTX**: paclitaxel; **PCR**: polymerase chain reaction; **FACS**: fluorescence-activated cell sorting; **IP**: Intraperitoneal; **eGFP**: green fluorescent protein; **ffLuc**: firefly luciferase; **ICP-MS**: inductively coupled plasma mass spectrometry; **MHC**: major histocompatibility complex; **PBMC**: peripheral blood mononuclear cells; **HLA**: human leukocyte antigen

References

1. Lengyel E. Ovarian cancer development and metastasis. Am J Pathol. 2010 Sep;177(3):1053–1064.
2. Ovarian cancer. Nat Rev Dis Primers. 2016 Aug 25;2:16062.
3. Huang B, Abraham WD, Zheng Y, Bustamante López SC, Luo SS, Irvine DJ. Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells. Sci Transl Med. 2015 Jun 10;7(291):291ra94.
4. Stephan MT, Moon JJ, Um SH, Bershteyn A, Irvine DJ. Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat Med. 2010 Sep;16(9):1035–1041.
5. Choi M-R, Stanton-Maxey KJ, Stanley JK, Levin CS, Bardhan R, Akin D, et al. A cellular Trojan Horse for delivery of therapeutic nanoparticles into tumors. Nano Lett. 2007 Dec;7(12):3759–3765.
6. Li L, Guan Y, Liu H, Hao N, Liu T, Meng X, et al. Silica nanorattle-doxorubicin-anchored mesenchymal stem cells for tumor-tropic therapy. ACS Nano. 2011 Sep 27;5(9):7462–7470.
7. Mooney R, Weng Y, Garcia E, Bhojane S, Smith-Powell L, Kim SU, et al. Conjugation of pH-responsive nanoparticles to neural stem cells improves intratumoral therapy. J Control Release. 2014 Oct 10;191:82–89.
8. Kendall SE, Najbauer J, Johnston HF, Metz MZ, Li S, Bowers M, et al. Neural stem cell targeting of glioma is dependent on phosphoinositide 3-kinase signaling. Stem Cells. 2008 Jun;26(6):1575–1586.
9. Mirahmadi N, Babaei MH, Vali AM, Dadashzadeh S. Effect of liposome size on peritoneal retention and organ distribution after intraperitoneal injection in mice. Int J Pharm. 2010 Jan 4;383(1-2):7–13.
10. Lu Z, Tsai M, Lu D, Wang J, Wientjes MG, Au JL-S. Tumor-penetrating microparticles for intraperitoneal therapy of ovarian cancer. J Pharmacol Exp Ther. 2008 Dec;327(3):673–682.

11. De Smet L, Ceelen W, Remon JP, Vervaet C. Optimization of drug delivery systems for intraperitoneal therapy to extend the residence time of the chemotherapeutic agent. ScientificWorldJournal. 2013 Mar 25;2013:720858.

12. Mader EK, Maeyama Y, Lin Y, Butler GW, Russell HM, Galanis E, et al. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clin Cancer Res. 2009 Dec 1;15(23):7246–7255.

13. Mader EK, Butler G, Dowdy SC, Mariani A, Knutson KL, Federspiel MJ, et al. Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer. J Transl Med. 2013 Jan 24;11:20.

14. Cao P, Mooney R, Tirughana R, Abidi W, Aramburo S, Flores L, et al. Intraperitoneal Administration of Neural Stem Cell-Nanoparticle Conjugates Targets Chemotherapy to Ovarian Tumors. Bioconjuc Chem. 2017 Jun 21;28(6):1767–1776.

15. Tiet P, Li J, Abidi W, Mooney R, Flores L, Aramburo S, et al. Silica coated paclitaxel nanocrystals enable neural stem cell loading for treatment of ovarian cancer. Bioconjuc Chem. 2019 May 15;30(5):1415–1424.

16. Portnow J, Synold TW, Badie B, Tirughana R, Lacey SF, D’Apuzzo M, et al. Neural Stem Cell-Based Anticancer Gene Therapy: A First-in-Human Study in Recurrent High-Grade Glioma Patients. Clin Cancer Res. 2017 Jun 15;23(12):2951–2960.

17. Tirughana R, Metz MZ, Li Z, Hall C, Hsu D, Beltzer J, et al. GMP Production and Scale-Up of Adherent Neural Stem Cells with a Quantum Cell Expansion System. Mol Ther Methods Clin Dev. 2018 Sep 21;10:48–56.

18. Mooney R, Majid AA, Batalla-Covello J, Machado D, Liu X, Gonzaga J, et al. Enhanced delivery of oncolytic adenovirus by neural stem cells for treatment of metastatic ovarian cancer. Mol Ther Oncolytics. 2019 Mar 29;12:79–92.

19. Cheng Y, Morshed R, Cheng S-H, Tobias A, Auffinger B, Wainwright DA, et al. Nanoparticle-programmed self-destructive neural stem cells for glioblastoma targeting and therapy. Small. 2013 Dec 20;9(24):4123–4129.

20. Ray A, Dittel BN. Isolation of mouse peritoneal cavity cells. J Vis Exp. 2010 Jan 28;(35).

21. Fiala JC. Reconstruct: a free editor for serial section microscopy. J Microsc. 2005 Apr;218(Pt 1):52–61.

22. Metz MZ, Gutova M, Lacey SF, Abramants Y, Vo T, Gilchrist M, et al. Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: implications for clinical use. Stem Cells Transl Med. 2013 Dec;2(12):983–992.

23. Mooney R, Roma L, Zhao D, Van Haute D, Garcia E, Kim SU, et al. Neural stem cell-mediated intratumoral delivery of gold nanorods improves photothermal therapy. ACS Nano. 2014 Dec 23;8(12):12450–12460.
24. Schnarr K, Mooney R, Weng Y, Zhao D, Garcia E, Armstrong B, et al. Gold nanoparticle-loaded neural stem cells for photothermal ablation of cancer. Adv Healthc Mater. 2013 Jul;2(7):976–982.

25. Sodek KL, Murphy KJ, Brown TJ, Ringuette MJ. Cell-cell and cell-matrix dynamics in intraperitoneal cancer metastasis. Cancer Metastasis Rev. 2012 Jun;31(1-2):397–414.

26. Ahmed AU, Thaci B, Tobias AL, Auffinger B, Zhang L, Cheng Y, et al. A preclinical evaluation of neural stem cell-based cell carrier for targeted antiglioma oncolytic virotherapy. J Natl Cancer Inst. 2013 Jul 3;105(13):968–977.

27. Ziu M, Schmidt NO, Cargioli TG, Aboody KS, Black PM, Carroll RS. Glioma-produced extracellular matrix influences brain tumor tropism of human neural stem cells. J Neurooncol. 2006 Sep;79(2):125–133.

28. Antunes MA, Abreu SC, Cruz FF, Teixeira AC, Lopes-Pacheco M, Bandeira E, et al. Effects of different mesenchymal stromal cell sources and delivery routes in experimental emphysema. Respir Res. 2014 Oct 3;15:118.

29. Eggenhofer E, Benseler V, Kroemer A, Popp FC, Geissler EK, Schlitt HJ, et al. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front Immunol. 2012 Sep 26;3:297.

30. O’Cearbhaill ED, Ng KS, Karp JM. Emerging medical devices for minimally invasive cell therapy. Mayo Clin Proc. 2014 Feb;89(2):259–273.

31. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006 Jan 5;354(1):34–43.

32. Markiewski MM, Nilsson B, Ekdahl KN, Mollnes TE, Lambris JD. Complement and coagulation: strangers or partners in crime? Trends Immunol. 2007 Apr;28(4):184–192.

33. Lassailly F, Griessinger E, Bonnet D. Microenvironmental contaminations induced by fluorescent lipophilic dyes used for noninvasive in vitro and in vivo cell tracking. Blood. 2010 Jul 1;115(26):5347–5354.

34. Mooney R, Majid AA, Batalla-Covello J, Machado D, Liu X, Gonzoaga J, et al. Enhanced delivery of oncolytic adenovirus by neural stem cells for treatment of metastatic ovarian cancer. Mol Ther Oncolytics. 2019 Mar 29;12:79-92.

35. Hammad M, Cornejo YR, Batalla-Covello J, Majid AA, Burke C, Liu Z, et al. Neural stem cells improve the delivery of oncolytic chimeric orthopoxvirus in a metastatic ovarian cancer model. Mol Ther Oncolytics. 2020 Sep 25;18:326–334.

36. Los G, Mutsaers PH, Lenglet WJ, Baldew GS, McVie JG. Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. Cancer Chemother Pharmacol. 1990;25(6):389–394.

37. Carlier C, Mathys A, De Jaeghere E, Steuperaert M, De Wever O, Ceelen W. Tumour tissue transport after intraperitoneal anticancer drug delivery. Int J Hyperthermia. 2017;33(5):534–542.

38. Heldin C-H, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer. 2004 Oct;4(10):806–813.
39. Levine EA, Ceelen WP. Intraperitoneal Cancer Therapy: Principles and Practice. Boca Raton: CRC Press; 2015.

40. Kampan NC, Madondo MT, McNally OM, Quinn M, Plebanski M. Paclitaxel and its evolving role in the management of ovarian cancer. Biomed Res Int. 2015 Jun 7;2015:413076.

41. Kuh HJ, Jang SH, Wientjes MG, Weaver JR, Au JL. Determinants of paclitaxel penetration and accumulation in human solid tumor. J Pharmacol Exp Ther. 1999 Aug;290(2):871–880.

42. Jang SH, Wientjes MG, Au JL. Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: effect of treatment schedule. J Pharmacol Exp Ther. 2001 Mar;296(3):1035–1042.

43. Lu D, Wientjes MG, Lu Z, Au JL-S. Tumor priming enhances delivery and efficacy of nanomedicines. J Pharmacol Exp Ther. 2007 Jul;322(1):80–88.

44. Jang SH, Wientjes MG, Au JL. Determinants of paclitaxel uptake, accumulation and retention in solid tumors. Invest New Drugs. 2001 May;19(2):113–123.

45. Yin M, Li X, Tan S, Zhou HJ, Ji W, Bellone S, et al. Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer. J Clin Invest. 2016 Nov 1;126(11):4157–4173.

46. Wilson T, Stark C, Holmbom J, Rosling A, Kuusilehto A, Tirri T, et al. Fate of bone marrow-derived stromal cells after intraperitoneal infusion or implantation into femoral bone defects in the host animal. J Tissue Eng. 2010 Aug 1;2010:345806.

47. Meyerrose TE, De Ugarte DA, Hofling AA, Herrbrich PE, Cordonnier TD, Shultz LD, et al. In vivo distribution of human adipose-derived mesenchymal stem cells in novel xenotransplantation models. Stem Cells. 2007 Jan;25(1):220–227.

48. Gao T, Yu Y, Cong Q, Wang Y, Sun M, Yao L, et al. Human mesenchymal stem cells in the tumour microenvironment promote ovarian cancer progression: the role of platelet-activating factor. BMC Cancer. 2018 Oct 19;18(1):999.

49. Bazhanov N, Ylostalo JH, Bartosh TJ, Tiblow A, Mohammadipoor A, Foskett A, et al. Intraperitoneally infused human mesenchymal stem cells form aggregates with mouse immune cells and attach to peritoneal organs. Stem Cell Res Ther. 2016 Feb 10;7:27.

50. Aboody KS, Brown A, Rainov NG, Bower KA, Liu S, Yang W, et al. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci USA. 2000 Nov 7;97(23):12846–12851.

51. Aboody KS, Najbauer J, Metz MZ, D’Apuzzo M, Gutova M, Annala AJ, et al. Neural stem cell-mediated enzyme/prodrug therapy for glioma: preclinical studies. Sci Transl Med. 2013 May 8;5(184):184ra59.

52. Bergström M, Ivarsson ML, Holmdahl L. Peritoneal response to pneumoperitoneum and laparoscopic surgery. Br J Surg. 2002 Nov;89(11):1465–1469.

53. Oosterling SJ, van der Bij GJ, van Egmond M, van der Sijp JR. Surgical trauma and peritoneal recurrence of colorectal carcinoma. Eur J Surg Oncol. 2005 Feb;31(1):29–37.